ONL Secures Orphan Designation for Retinal Detachment Candidate

Ann Arbor, Mich.-based ONL Therapeutics has won orphan drug designation from the FDA for ONL 1204, a candidate to treat retinal detachment.

ONL 1204 is designed to protect retinal cells from death resulting from disease or conditions.

As a result of the designation, ONL may gain certain incentives, including tax credits and a seven-year period of market exclusivity.